The successful bridging or downstaging to LT criteria in patients undergoing Y90-RE therapy for HCC is associated with a lower ALBI grade, lower CP class, lower BCLC stage, HCC diagnosis with DCE CT or MRI, normal/higher albumin levels, a more limited tumor burden, left lobar disease, and the absence of HBV-associated cirrhosis, baseline abdominal pain, or fatigue. This evidence concerns the gene ALB and hepatocellular carcinoma.